ANDA 216164, held by Knack. Levofloxacin.
As of Nov 16, 2026, ANDA 216164 (Levofloxacin In Dextrose 5% In Plastic Container), held by Knack, was first approved by FDA on Jan 29, 2024, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2024 | Original application | Approved | None posted |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 250MG/50ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Discontinued |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 500MG/100ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Discontinued |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 750MG/150ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Discontinued |
| Sep 20, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 29, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters